← All trials
NCT05016947
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 24, 2021
- Primary completion
- Jun 23, 2023
- Completion date
- Jun 23, 2026
- First posted
- Aug 23, 2021
- Last posted
- Oct 20, 2021
- Enrollment
- 26
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityReponsible party - principal investigator
- Harvard UniversityOverall official - principal investigator
- AbbVieCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.